Surveyed U.S. Neurologists Would Prescribe Biogen Idec's Tecfidera to 20 ... PR Newswire (press release) Clinical data and the opinions of thought leaders interviewed by Decision Resources indicate that other emerging agents—Lemtrada, ocrelizumab and AbbVie/Biogen Idec's daclizumab—have advantages in reducing ARR over Teva's Copaxone, the ... |
